08:49 AM EDT, 09/30/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Monday that it has submitted marketing authorization applications to regulatory authorities in the UK, Switzerland, Australia, and Singapore for sebetralstat, an investigational treatment for hereditary angioedema attacks in adults and adolescents aged 12 years and older.

The submissions are based on data from a clinical trial in which sebetralstat met its primary endpoint as well as other ongoing trials, the company said.

Hereditary angioedema is a rare genetic condition that causes attacks of tissue swelling in various locations of the body that can be life-threatening.

Shares were up over 1% in recent premarket activity.

Price: 12.50, Change: +0.16, Percent Change: +1.30